Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Regulatory News (PRTC)

Share Price Information for PureTech (PRTC)

Share Price is delayed by 15 minutes
Get Live Data
127.60    2.60 (2.08%)
Bid:
127.60
Ask:
128.40
Spread: 0.80 (0.627%)
Market Cap: £310.60m
PRTC Live PriceLast checked at - London Stock Exchange

Intraday PureTech Share Chart

Holding(s) in Company

6 Jul 2020 07:01

RNS Number : 0567S
PureTech Health PLC
06 July 2020
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

Puretech Health Plc

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (Please specify); As of 1 July 2020, following Jupiter's acquisition of Merian, the Chain of Control for Jupiter Fund Management plc, which includes Jupiter Asset Management, has changed and any disclosures going forward will be notified by Jupiter Fund Management Plc (JFM). As such this disclosure indicates that JAM no longer has responsibility for filing TR1 notifications and this responsibility has been transferred to JFM as the parent entity.

 

X

3. Details of person subject to the notification obligationiv

Name

Jupiter Asset Management Limited

City and country of registered office (if applicable)

4. Full name of shareholder(s) (if different from 3.)v

Name

Northern Trust Nominees Limited

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

1st July 2020

6. Date on which issuer notified (DD/MM/YYYY):

3rd July 2020

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

Below 5%

N/A

Below 5%

285,512,461

Position of previous notification (if

applicable)

5.04%

N/A

5.04%

237,429,696

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Ordinary Shares

 

 

GB00BY2Z0H74

N/A

Below 5%

N/A

Below 5%

SUBTOTAL 8. A

Below 5%

Below 5%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

 

N/A

 

N/A

 

N/A

 

N/A

 

N/A

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

 

N/A

 

N/A

 

N/A

 

N/A

 

N/A

 

N/A

SUBTOTAL 8.B.2

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

X

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Jupiter Fund Management Plc

Jupiter Fund Management Group Limited

Jupiter Asset Management Group Limited

Knightsbridge Asset Management Limited

Jupiter Investment Management Group Limited

Jupiter Asset Management Limited

Below 5%

N/A

Below 5%

10. In case of proxy voting, please identify:

Name of the proxy holder

N/A

The number and % of voting rights held

N/A

The date until which the voting rights will be held

N/A

11. Additional informationxvi

 

Contact :Jon Watson

 

Telephone Number : 0203 817 1672

 

Place of completion

London, UK

Date of completion

 

3rd July 2020

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLRAMLTMTJMBLM
Date   Source Headline
21st Jul 202012:02 pmRNSPrice Monitoring Extension
17th Jul 20207:00 amRNSHolding(s) in Company
16th Jul 20201:04 pmRNSVor Appoints Biotech Finance Leader to BOD
14th Jul 20201:04 pmRNSVor Names Oncology Drug Development Expert as CMO
8th Jul 20201:32 pmRNSSonde Launches Voice Health Screening for COVID-19
8th Jul 202012:02 pmRNSPrice Monitoring Extension
7th Jul 202012:03 pmRNSPureTech’s Vor Raises $110M Series B Financing
6th Jul 20207:01 amRNSHolding(s) in Company
6th Jul 20207:00 amRNSHolding(s) in Company
1st Jul 20207:00 amRNSTotal Voting Rights
23rd Jun 20201:48 pmRNSKaruna Positive FDA End of Phase 2 Meeting
23rd Jun 20207:00 amRNSAkili Gets European Approval to Market EndeavorRx
22nd Jun 20202:00 pmRNSPRTC Presents New Immuno-oncology Data at AACR
22nd Jun 20207:00 amRNSPDMR Notification RSU Vesting
18th Jun 202012:01 pmRNSGelesis China Deal $35M and up to $388M milestones
16th Jun 20207:00 amRNSAkili Granted FDA Clearance for ADHD Treatment
15th Jun 202012:07 pmRNSSecond Price Monitoring Extn
15th Jun 202012:02 pmRNSPrice Monitoring Extension
12th Jun 202012:08 pmRNSSecond Price Monitoring Extn
12th Jun 202012:03 pmRNSPrice Monitoring Extension
12th Jun 20207:00 amRNSResult of AGM
10th Jun 202012:08 pmRNSSecond Price Monitoring Extn
10th Jun 202012:02 pmRNSPrice Monitoring Extension
9th Jun 20207:00 amRNSPositive Data from Vedanta IBD Clinical Studies
4th Jun 20207:00 amRNSPositive FDA Feedback on Follica
2nd Jun 20207:00 amRNSGelesis Approved to Market Plenity in Europe
28th May 20207:00 amRNSPRTC Targets COVID-19 Post-Recovery Complications
27th May 20207:00 amRNSPRTC to Present at Jefferies Virtual Conference
26th May 20201:05 pmRNSVor Appoints CFO Nathan Jorgensen
26th May 20207:00 amRNSPRTC Receives Another $45M from Affiliate Shares
22nd May 202012:02 pmRNSPrice Monitoring Extension
21st May 20207:00 amRNSPDMR DEALING - PURCHASE OF SHARES
20th May 20207:05 amRNSPDMR DEALING - PURCHASE OF SHARES
20th May 20207:00 amRNSPDMR Notification – Transfer From Trust
19th May 20207:00 amRNSPDMR DEALING - PURCHASE OF SHARES
18th May 202012:02 pmRNSPrice Monitoring Extension
18th May 20207:00 amRNSPDMR DEALING - PURCHASE OF SHARES
18th May 20207:00 amRNSPDMR DEALING - PURCHASE OF SHARES
15th May 20207:00 amRNSPDMR DEALING - PURCHASE OF SHARES
6th May 202012:07 pmRNSSecond Price Monitoring Extn
6th May 202012:02 pmRNSPrice Monitoring Extension
4th May 202012:02 pmRNSPrice Monitoring Extension
23rd Apr 202012:07 pmRNSSecond Price Monitoring Extn
23rd Apr 202012:03 pmRNSPrice Monitoring Extension
22nd Apr 202011:00 amRNSAkili ADHD Treatment Now Available in US
21st Apr 20204:41 pmRNSSecond Price Monitoring Extn
21st Apr 20204:36 pmRNSPrice Monitoring Extension
21st Apr 202012:07 pmRNSSecond Price Monitoring Extn
21st Apr 202012:02 pmRNSPrice Monitoring Extension
14th Apr 20207:00 amRNSPRTC to Present at Virtual Needham Conference

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.